Research map: The risk of cardiovascular events in metabolic dysfunction–associated steatotic liver disease according to fibrosis stage and diabetes status: A cohort study

Back to the article

Papers in this map

  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases · Naga Chalasani · 2017 · 7417 citations · Cited by this paper
  2. CRISPLD2 protects against liver inflammation and fibrosis via GRP78 to repress HMGB1/TLR4 axis–mediated STING palmitoylation · 2026 · Related
  3. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ · Richard K. Sterling · 2006 · 5001 citations · Cited by this paper
  4. Neoadjuvant therapy in primary liver cancer: From the missing piece to a new paradigm · 2026 · Related
  5. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3032 citations · Cited by this paper
  6. Prospective validation of a real-time natural language processing pipeline for the extraction of elastography results from electronic health record data · 2026 · Related
  7. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease · Mary Eugenia Rinella · 2023 · 2555 citations · Cited by this paper
  8. Reply: High mortality at safety-net hospitals for patients with cirrhosis · 2026 · Related
  9. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up · Mattias Ekstedt · 2014 · 2304 citations · Cited by this paper
  10. Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH · 2026 · Related
  11. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) · Frank Tacke · 2024 · 2049 citations · Cited by this paper
  12. Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies · 2026 · Related
  13. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis · Parambir Singh Dulai · 2017 · 1972 citations · Cited by this paper
  14. IL15-mediated crosstalk between LSECs and CD8⁺ tissue-resident memory T cells drives alcohol-associated hepatitis · 2026 · Related
  15. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease · Donna K. Arnett · 2019 · 1915 citations · Cited by this paper
  16. Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study · 2026 · Related
  17. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update · Annalisa Berzigotti · 2021 · 1896 citations · Cited by this paper
  18. Contemporary global epidemiology of cirrhosis · 2026 · Related
  19. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary · Scott M. Grundy · 2018 · 1763 citations · Cited by this paper
  20. The role of ammonia in chronic liver disease · 2026 · Related
  21. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments · Giovanni Targher · 2021 · 855 citations · Cited by this paper
  22. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study · Eduardo Vilar‐Gómez · 2018 · 814 citations · Cited by this paper
  23. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis · Michael Huan Le · 2021 · 722 citations · Cited by this paper
  24. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis · Alessandro Mantovani · 2021 · 671 citations · Cited by this paper
  25. Past, present and future perspectives in nonalcoholic fatty liver disease · Arun Jayant Sanyal · 2019 · 541 citations · Cited by this paper
  26. Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · Sunil V. Rao · 2025 · 410 citations · Cited by this paper
  27. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association · Kenneth J. Cusi · 2025 · 315 citations · Cited by this paper
  28. Prediabetes and Cardiovascular Disease · Ben Brannick · 2018 · 295 citations · Cited by this paper
  29. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD · Grace En Hui Lim · 2021 · 252 citations · Cited by this paper
  30. A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know · Mark Dhinesh Muthiah · 2021 · 108 citations · Cited by this paper
  31. Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease · Joana Vieira Barbosa · 2022 · 102 citations · Cited by this paper
  32. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease · Eric M. Przybyszewski · 2021 · 72 citations · Cited by this paper
  33. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease · Mi Na Kim · 2024 · 60 citations · Cited by this paper
  34. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment · Eleni Michalopoulou · 2025 · 50 citations · Cited by this paper
  35. KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 · Won Sohn · 2025 · 46 citations · Cited by this paper
  36. Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis · Ji Won Han · 2024 · 28 citations · Cited by this paper
  37. Identification of high-risk subjects in nonalcoholic fatty liver disease · Christiane Stern · 2022 · 23 citations · Cited by this paper
  38. Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease · Hye Won Lee · 2025 · 15 citations · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)